Article: Dopaminergic treatment hallucinations not 'benign'.(Clinical Rounds)

SAN DIEGO -- So-called benign hallucinations associated with dopaminergic treatment for Parkinson's disease rarely remain "benign," calling into question the accuracy of the term.

Researchers at Rush University in Chicago studied the clinical progression of 48 patients with Parkinson's disease who were diagnosed with hallucinations characterized by the patient's retention of the insight that the hallucinations are unreal.

These hallucinations have been called benign, and traditionally have been associated with a Unified Parkinson Disease Rating Scale (UPDRS) Thought Disorder score of 2.

In 2 years, just 2 of the 48 patients at Rush continued to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!